ADAMTS13 and thrombotic thrombocytopenic purpura: The striking success of TPE as upfront emergency therapy in TTP, reducing morbidity and mortality from 90% in untreated patients to below 20%, led to broad application in other forms of TMA, independent of ADAMTS13 status [18,19].